7 ms·
I'm not sure that anyone ever _really_ thought it improved survival. Just cutting time in hospital would be useful enough.
by rsynnott 6y ago
I'm not sure that anyone ever _really_ thought it improved survival. Just cutting time in hospital would be useful enough.
- boomboomsubban 6y agoYou generally spend time in the hospital when your condition is critical. So, if it cut hospital time, it would improve survival.
- petemir 6y agoOr kill you faster.
- recursive 6y agoDead people don't spend time in the hospital. Therefore, being dead improves survival.
- boomboomsubban 6y agoI assume they track hospital time by the discharge date, the deceased would be classified separately.
- recursive 6y agoI'm not making any assumptions.
- boomboomsubban 6y agoI don't understand what you're doing. For more clarity, I'll change my statement to >So, unless you die, if it cut hospital time, it would improve survival.
- madacol 6y agoThat doesn't makes sense to me, it can make recoveries faster, while still making dying faster or slower, and still have the same mortality. They are all independent consequences
- boomboomsubban 6y agoEvery day that you are in critical condition carries a relatively high risk of death. Beyond that, hospitals are full of other diseases, and staying in one when your immune system is already taking a beating is dangerous. The drug may have some negative effect on the chance that you'll die each day, but it is unlikely that the effect would be strong enough to prefer spending more time in critical condition. And getting cured faster will allow your immune system to be more able to fight off other risks.
- recursive 6y ago>So, unless you die, if it cut hospital time, it would improve survival. Maybe that's what usually happens. It's not hard for me to imagine that it could improve survival for some, but has fatal side effects for some percentage. The numbers could be arranged so that survival doesn't change but average hospital stay is lower. Is this the case? Probably not, but I have no idea.
- divbzero 6y agoThis too is my recollection of the initial clinical trial results — shortened course of disease but no indication of improved survival. The new WHO study reinforces the initial evidence but is not new news. Edit: The closest Gilead has come to suggesting a survival advantage from Remdesivir was a comparative analysis presented in July [1]. The analysis was highlighted as inconclusive because it wasn’t a double-blinded placebo-controlled study, which is the gold standard for clinical trials. [1]: https://www.bloomberg.com/news/articles/2020-07-10/gilead-s-remdesivir-linked-to-62-reduction-in-mortality-risk https://www.bloomberg.com/news/articles/2020-07-10/gilead-s-...
- koheripbal 6y agoThe biggest limitation to this drug is that it probably works very well IF given in the first 12 hours of infection when viral replication is highest. The problem is that since it's intravenous, it's hard to justify giving it to people BEFORE they seem sick. Naturally patients and doctors are pressured to treat the sickest patients first, and so they get the Remdesivir, despite it likely not doing much so late in sickness. Ideally, if we could identify people highest at risk, and early in their disease - THEY should be given the drug very rapidly. ...but again, without that identification step, it's very hard to justify giving someone an experimental treatment.